Literature DB >> 24462197

Stress cardiomyopathy: yet another type of neurocardiogenic injury: 'stress cardiomyopathy'.

Maciej Wybraniec1, Katarzyna Mizia-Stec2, Lukasz Krzych3.   

Abstract

Tako-tsubo syndrome pertains to rare acquired cardiomyopathies, characterized by left ventricular dyskinesia and symptomatology typical for acute myocardial infarction (AMI). Despite its low incidence and relatively benign course, stress cardiomyopathy should be thoroughly differentiated from AMI. The importance of tako-tsubo consists of the fact that its manifestation initially resembles AMI. Despite seemingly low incidence of tako-tsubo, acute coronary syndromes globally constitute a major epidemiological issue and both clinical entities should be accurately differentiated. Many patients present with only mild troponin release, certain extent of regional wall motion abnormalities (RWMA) and absence of hemodynamically significant coronary artery stenosis. In such instances, a careful interview aimed at preceding emotional or physical traumatic event should be undertaken. The subsequent verification of the diagnosis is based upon prompt recovery of contractile function. Although precise diagnostic criteria were formulated, symptomatology of tako-tsubo might be clinically misleading due to the possibility of concomitant coronary vasospasm, atypical pattern of RWMA and presence of non-significant coronary disease. For this reason, its exact rate might be underestimated. Stress cardiomyopathy reflects merely a single aspect of a much wider range of neurocardiogenic injury, which encompasses cardiac dysfunction associated with subarachnoid hemorrhage, intracranial hypertension and cerebral ischemia. Both psychological and physical insult to central nervous system may trigger a disastrous response of sympathetic nervous system, eventually leading to end-organ catecholamine-mediated damage. This review sought to delineate the phenomenon of tako-tsubo cardiomyopathy and deliver evidence for common pathophysiology of the broad spectrum of neurocardiogenic injury.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Catecholamine toxicity; Neurocardiogenic injury; Stress cardiomyopathy; Tako-tsubo

Mesh:

Substances:

Year:  2013        PMID: 24462197     DOI: 10.1016/j.carpath.2013.12.003

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  5 in total

Review 1.  Understanding stress cardiomyopathy.

Authors:  Steven M Hollenberg
Journal:  Intensive Care Med       Date:  2015-08-14       Impact factor: 17.440

Review 2.  [Troponin elevation in acute ischemic stroke-unspecific or acute myocardial infarction? : Diagnostics and clinical implications].

Authors:  M Kruska; C Fastner; J F Scheitz; A Kolb; M Rutsch; T Papavassiliu; M Borggrefe; A Alonso; I Akin; K Szabo; S Baumann
Journal:  Herz       Date:  2020-07-06       Impact factor: 1.443

3.  Ischemic Versus Non-Ischemic (Neurogenic) Myocardial Contractility Impairment in Acute Coronary Syndromes: Prevalence and Impact on Left Ventricular Systolic Function Recovery.

Authors:  Paweł Iwaszczuk; Bartosz Kołodziejczyk; Tomasz Kruczek; Leszek Drabik; Wojciech Płazak; Monika Komar; Piotr Podolec; Piotr Musiałek
Journal:  Med Sci Monit       Date:  2018-06-02

4.  The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities.

Authors:  Louis Maximilian Buja; Dwayne A Wolf; Bihong Zhao; Bindu Akkanti; Michelle McDonald; Laura Lelenwa; Noah Reilly; Giulia Ottaviani; M Tarek Elghetany; Daniel Ocazionez Trujillo; Gabriel M Aisenberg; Mohammad Madjid; Biswajit Kar
Journal:  Cardiovasc Pathol       Date:  2020-05-07       Impact factor: 2.185

5.  Acute Disseminated Encephalomyelitis with Seizures and Myocarditis: A Fatal Triad.

Authors:  Hanne Lademann; Astrid Bertsche; Axel Petzold; Fred Zack; Andreas Büttner; Jan Däbritz; Christina Hauenstein; Erik Bahn; Christian Spang; Daniel Reuter; Philipp Warnke; Johannes Ehler
Journal:  Medicina (Kaunas)       Date:  2020-06-04       Impact factor: 2.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.